KIF3A and neoplasm: To validate the potential tumour suppressor function of KIF3A in NSCLC, we first examined the expression of KIF3A and β-catenin in 233 tumour tissue samples from 110 NSCLC patients who had multiple synchronous or metachronous tumours.